<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008462</url>
  </required_header>
  <id_info>
    <org_study_id>2241.00</org_study_id>
    <secondary_id>NCI-2009-01334</secondary_id>
    <secondary_id>2241.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01008462</nct_id>
  </id_info>
  <brief_title>Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies autologous peripheral blood stem cell transplant followed by
      donor bone marrow transplant in treating patients with high-risk Hodgkin lymphoma,
      non-Hodgkin lymphoma, multiple myeloma, or chronic lymphocytic leukemia. Autologous stem cell
      transplantation uses the patient's stem cells and does not cause graft versus host disease
      (GVHD) and has a very low risk of death, while minimizing the number of cancer cells.
      Peripheral blood stem cell (PBSC) transplant uses stem cells from the patient or a donor and
      may be able to replace immune cells that were destroyed by chemotherapy. These donated stem
      cells may help destroy cancer cells. Bone marrow transplant known as a nonmyeloablative
      transplant uses stem cells from a haploidentical family donor. Autologous peripheral blood
      stem cell transplant followed by donor bone marrow transplant may work better in treating
      patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic
      lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Event-free survival (EFS) at 1-year after autograft.

      SECONDARY OBJECTIVES:

      I. Relapse rates at 1-year after autograft.

      II. Overall survival (OS) at 1-year after autograft.

      III. Incidence of grades II-IV acute GVHD and chronic extensive GVHD.

      IV. Non-relapse mortality (NRM) at 200 days and 1 year after allograft.

      V. Donor engraftment at day +84.

      VI. Incidence of infections.

      OUTLINE:

      CONDITIONING REGIMEN 1 (lymphoma, Waldenstrom macroglobulinemia, or chronic lymphocytic
      leukemia [CLL] with no dose limiting radiation or significant comorbidities: Patients receive
      cyclophosphamide intravenously (IV) on days -6 and -5. Patients undergo high-dose total body
      irradiation (TBI) twice daily (BID) on days -3 to -1.

      CONDITIONING REGIMEN 2 (lymphoma, Waldenstrom Macroglobulinemia, CLL, with prior
      dose-limiting radiation, or significant comorbidities): Patients receive carmustine IV on day
      -7, etoposide IV BID on days -6 to -3, cytarabine IV BID on days -6 to -3, and melphalan IV
      on day -2.

      CONDITIONING REGIMEN 3 (multiple myeloma or plasma cell leukemia, with no significant renal
      insufficiency or other significant comorbidities): Patients receive high-dose melphalan IV on
      day -2.

      CONDITIONING REGIMEN 4 (multiple myeloma or plasma cell leukemia, with significant renal
      insufficiency or other significant comorbidities): Patients receive lessened dose of
      melphalan IV on day -2.

      PBSC TRANSPLANTATION: All patients undergo autologous PBSC transplantation on day 0.

      WAITING INTERVAL: Between 40 and 120 days.

      NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV once daily
      (QD) on days -6 to -2 and cyclophosphamide IV QD on days -6 to -5 and day 3. Patients infused
      with donor's peripheral blood stem cells will additionally receive cyclophosphamide IV on day
      4. Patients undergo low-dose TBI on day -1.

      ALLOGENEIC BONE MARROW TRANSPLANTATION: Patients undergo donor bone marrow transplantation on
      day 0.

      GRAFT VERSUS HOST DISEASE PROPHYLAXIS: Beginning on day 4, patients receive tacrolimus orally
      (PO) or IV and taper beginning on day 86 if no graft-versus-host disease. Patients also
      receive mycophenolate mofetil PO thrice daily (TID) on days 4 - 35.

      PERIPHERAL BLOOD COUNT SUPPORT: Patients receive filgrastim (G-CSF) IV or subcutaneously (SC)
      beginning from day 4 and continue till blood counts recover.

      ALLOGENEIC PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) TRANSPLANTATION: Patients undergo donor
      PBMC transplantation on day 0.

      GRAFT VERSUS HOST DISEASE PROPHYLAXIS: Beginning on day 5, patients receive tacrolimus orally
      (PO) or IV and taper beginning on day 86 if no graft-versus-host disease. Patients also
      receive mycophenolate mofetil PO thrice daily (TID) on days 5 - 35.

      PERIPHERAL BLOOD COUNT SUPPORT: Patients receive filgrastim IV or SC beginning from day 5 and
      continue till blood counts recover.

      After completion of study treatment, patients are followed up annually for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2010</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>1 Year post-autograft</time_frame>
    <description>Number of patients surviving without relapsed/progressive disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Relapsed/Progressive Disease</measure>
    <time_frame>1 year post-autograft</time_frame>
    <description>Relapse/Progression defined as:
Nodes, liver, and/or spleen ≥50% increased or new by physical exam / imaging studies.
Circulating lymphocytes ≥50% increased by morphology and/or flow cytometry. Richter's transformation by lymph node biopsy .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year post-autograft</time_frame>
    <description>Number of patients surviving one year post-autograft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Grade II-IV Acute Graft-versus-Host-Disease and/or Chronic Extensive Graft-versus-Host-Disease</measure>
    <time_frame>1 year post-allograft,</time_frame>
    <description>aGVHD The diagnosis of aGVHD is identified through various stages and grading of the disease related to Skin (Rash), Gut (Diarrhea, Nausea/vomiting and/or anorexia) and the liver (Bilirubin) assessed by severity and grading scale outlined in the section Grafts vs Hosts by Sullivan (1999).
GVHD Grades Grade I: 1-2 Skin Rash; No gut or liver involvement Grade II: Stage 1-3 Skin rash; Stage 1 gut and/or stage 1 liver involvement Grade III: Stage 2-4 gut involvement and/or stage 2-4 liver involvement with or without rash Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death
CGVHD The diagnosis of cGVHD requires at least one manifestation that is distinctive for chronic GVHD as opposed to acute GVHD. In all cases, infection and others causes must be ruled out in the differential diagnosis of chronic GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality (NRM)</measure>
    <time_frame>200 days and 1 Year post-allograft</time_frame>
    <description>Number of patients with non-relapse mortalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Engrafted</measure>
    <time_frame>Day 84 post-allograft</time_frame>
    <description>Number of patients with donor engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Had Infections</measure>
    <time_frame>1 Year post-autograft</time_frame>
    <description>Number of patients who had infections.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>B-Cell Prolymphocytic Leukemia</condition>
  <condition>Hypodiploidy</condition>
  <condition>Loss of Chromosome 17p</condition>
  <condition>Plasma Cell Leukemia</condition>
  <condition>Progression of Multiple Myeloma or Plasma Cell Leukemia</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Childhood Hodgkin Lymphoma</condition>
  <condition>Recurrent Childhood Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Chronic Lymphocytic Leukemia</condition>
  <condition>Recurrent Plasma Cell Myeloma</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Plasma Cell Myeloma</condition>
  <condition>Refractory Small Lymphocytic Lymphoma</condition>
  <condition>t(14;16)</condition>
  <condition>t(4;14)</condition>
  <condition>T-Cell Prolymphocytic Leukemia</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo donor HCT</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo donor HCT</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous PBSC transplant</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>Autologous Hematopoietic Cell Transplantation</other_name>
    <other_name>autologous stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous-donor tandem HCT</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>auto-allo HCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Becenum</other_name>
    <other_name>Becenun</other_name>
    <other_name>BiCNU</other_name>
    <other_name>Bis(chloroethyl) Nitrosourea</other_name>
    <other_name>Bis-Chloronitrosourea</other_name>
    <other_name>Carmubris</other_name>
    <other_name>Carmustin</other_name>
    <other_name>Carmustinum</other_name>
    <other_name>FDA 0345</other_name>
    <other_name>Gliadel</other_name>
    <other_name>N,N'-Bis(2-chloroethyl)-N-nitrosourea</other_name>
    <other_name>Nitrourean</other_name>
    <other_name>Nitrumon</other_name>
    <other_name>SK 27702</other_name>
    <other_name>SRI 1720</other_name>
    <other_name>WR-139021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine nitrogen mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo donor HCT</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (autologous HCT, donor HCT)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have the capacity to give informed consent

          -  Detectable tumor prior to mobilization regimen

          -  Patients with stored autologous stem cells will be allowed

          -  Stem cells from an identical donor could be used for autologous hematopoietic cell
             transplant (HCT)

          -  Marrow is the preferred source of stem cells from the HLA-haploidentical donor,
             however, peripheral blood mononuclear cells (PBMC) could be used as stem cell source,
             after clearance with the Fred Hutchinson Cancer Research Center (FHCRC) principal
             investigator, in the case of difficulties or contraindications to bone marrow harvest
             from the donor

          -  Cross-over to other tandem autologous-allogeneic research protocol (#1409 or other
             appropriate protocol) will be allowed if a suitable HLA-matched related or unrelated
             donor is identified before receiving the allogeneic transplantation and if the patient
             meets the eligibility criteria of the subsequent study

          -  Cross-over from other tandem autologous-allogeneic research protocol (#1409 or other
             appropriate protocol) will be allowed if the patient loses the suitable HLA-matched
             related or unrelated donor but has an available HLA-haploidentical donor before
             receiving the allogeneic transplantation and if the patient meets the eligibility
             criteria of the subsequent study

          -  Lymphoma: patients with

               -  Diagnosis of non-Hodgkin lymphoma (NHL) or Hodgkin's lymphoma (HL), of any
                  histological grade

               -  Refractory or relapsed disease after standard chemotherapy

               -  High risk of early relapse following autograft alone

          -  Waldenstrom's macroglobulinemia: must have failed 2 courses of therapy

          -  CLL:

               -  Patients with either a:

                    -  Diagnosis of T-cell CLL or T-cell prolymphocytic leukemia (PLL) who have
                       failed initial chemotherapy, patients with T cell CLL or PLL or

                    -  Diagnosis of B-cell CLL, B-cell small lymphocytic lymphoma, or B-cell CLL
                       that progressed to PLL who either:

                         1. Failed to meet National Cancer Institute (NCI) Working Group criteria
                            for complete or partial response after therapy with a regimen
                            containing fludarabine (or another nucleoside analog, e.g.
                            2-chlorodeoxyadenosine [CDA], pentostatin) or experience disease
                            relapse within 12 months after completing therapy with a regimen
                            containing fludarabine (or another nucleoside analog)

                         2. Failed any aggressive chemotherapy regimen, such as fludarabine,
                            cyclophosphamide and rituximab (FCR), at any time point

                         3. Have &quot;17p deletion&quot; cytogenetic abnormality and relapsed at any time
                            point after initial chemotherapy

               -  Harvesting criteria for autologous HCT:

                    -  Previously collected PBMC may be used

                    -  Circulating CLL cells &lt; 5000

               -  Marrow involvement with CLL cells &lt; 50%

          -  Multiple myeloma (MM): patients who

               -  Have received induction therapy for a minimum of 4 cycles

               -  In addition, patients must meet at least one of the following criteria I-IX
                  (I-VII at time of diagnosis or pre-autograft):

                    -  Any abnormal karyotype by metaphase analysis except for isolated t(11,14),

                    -  Fluorescent in situ hybridization (FISH) translocation 4:14,

                    -  FISH translocation 14:16,

                    -  FISH deletion 17p,

                    -  Beta2 (B2)-microglobulin &gt; 5.5 mg/ml,

                    -  Cytogenetic hypodiploidy

                    -  Plasmablastic morphology (&gt;= 2%)

                    -  Recurrent or non-responsive (less than partial remission [PR]) MM after at
                       least two different lines of conventional chemotherapy

                    -  Progressive MM after a previous autograft (provided stored autologous
                       cluster of differentiation [CD]34 cells are available)

          -  Plasma cell leukemia: after induction chemotherapy

          -  DONOR: Related donors who are genotypically identical for one HLA haplotype and who
             may be mismatched at the HLA-A, -B, -C or DRB1 loci of the unshared haplotype with the
             exception of single HLA-A, -B or -C allele mismatches

          -  DONOR: Marrow is the preferred source of stem cells from the HLA-haploidentical donor,
             however PBMC could be used as stem cell source, after clearance with the FHCRC
             principal investigator, in the case of difficulties or contraindications to bone
             marrow harvest from the donor

          -  DONOR: In the case that PBMC will be used as stem cell source, ability of donors &lt; 18
             years of age to undergo apheresis without use of a vascular access device; vein check
             must be performed and verified by an apheresis nurse prior to arrival at the Seattle
             Cancer Care Alliance (SCCA)

          -  DONOR: Age &gt;= 12 years of age

        Exclusion Criteria:

          -  Life expectancy severely limited by disease other than malignancy

          -  Seropositive for the human immunodeficiency virus

          -  Female patients who are pregnant or breastfeeding

          -  Fertile men or women unwilling to use contraceptive techniques during and for 12
             months following treatment

          -  Central nervous system (CNS) involvement with disease refractory to intrathecal
             chemotherapy

          -  Patients with active non-hematological malignancies (except non-melanoma skin cancers)
             or those with non-hematological malignancies (except non-melanoma skin cancers) who
             have been rendered with no evidence of disease, but have a greater than 20% chance of
             having disease recurrence within 5 years

               -  This exclusion does not apply to patients with non-hematologic malignancies that
                  do not require therapy

          -  Patients with fungal infection and radiological progression after receipt of
             amphotericin B or active triazole for greater than 1 month

          -  Symptomatic coronary artery disease or ejection fraction &lt; 40% or other cardiac
             failure requiring therapy (or, if unable to obtain ejection fraction, shortening
             fraction of &lt; 26%); ejection fraction is required if the patient has a history of
             anthracyclines or history of cardiac disease; patients with a shortening fraction &lt;
             26% may be enrolled if approved by a cardiologist

          -  Corrected diffusion capacity of the lungs for carbon monoxide (DLCO) &lt; 50% of
             predicted, forced expiratory volume in one second (FEV1) &lt; 50% of predicted, and/or
             receiving supplementary continuous oxygen; the FHCRC principal investigator (PI) of
             the study must approve of enrollment of all patients with pulmonary nodules

          -  Patient with clinical or laboratory evidence of liver disease will be evaluated for
             the cause of liver disease, its clinical severity in terms of liver function, bridging
             fibrosis, and the degree of portal hypertension; the patient will be excluded if
             he/she is found to have fulminant liver failure, cirrhosis of the liver with evidence
             of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding
             esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic
             dysfunction evinced by prolongation of the prothrombin time, ascites related to portal
             hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral
             hepatitis with total serum bilirubin &gt; 3 mg/dL, and symptomatic biliary disease

          -  Karnofsky score &lt; 50% for adult patients

          -  Lansky play-performance score &lt; 40 for pediatric patients

          -  Patient with poorly controlled hypertension despite multiple antihypertensives

          -  DONOR: Donor-recipient pairs in which the HLA-mismatch is only in the
             host-versus-graft (HVG) direction

          -  DONOR: Infection with human immunodeficiency virus (HIV)

          -  DONOR: Weight &lt; 20 kg

          -  DONOR: A positive anti-donor cytotoxic crossmatch
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Sorror</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 4, 2009</study_first_submitted>
  <study_first_submitted_qc>November 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2009</study_first_posted>
  <results_first_submitted>May 8, 2019</results_first_submitted>
  <results_first_submitted_qc>May 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 29, 2019</results_first_posted>
  <last_update_submitted>May 31, 2019</last_update_submitted>
  <last_update_submitted_qc>May 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Leukemia, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic, T-Cell</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT01008462/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Autologous HCT, Donor HCT)</title>
          <description>Allogeneic Bone Marrow Transplantation: Undergo donor HCT
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant
Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT
Carmustine: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative study
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Peripheral Blood Stem Cell Transplantation: Undergo donor HCT
Tacrolimus: Given IV or PO
Total-Body Irradiation: Undergo TBI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Autologous HCT, Donor HCT)</title>
          <description>Allogeneic Bone Marrow Transplantation: Undergo donor HCT
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant
Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT
Carmustine: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative study
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Peripheral Blood Stem Cell Transplantation: Undergo donor HCT
Tacrolimus: Given IV or PO
Total-Body Irradiation: Undergo TBI</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="15" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event-Free Survival (EFS)</title>
        <description>Number of patients surviving without relapsed/progressive disease</description>
        <time_frame>1 Year post-autograft</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Autologous HCT, Donor HCT)</title>
            <description>Allogeneic Bone Marrow Transplantation: Undergo donor HCT
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant
Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT
Carmustine: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative study
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Peripheral Blood Stem Cell Transplantation: Undergo donor HCT
Tacrolimus: Given IV or PO
Total-Body Irradiation: Undergo TBI</description>
          </group>
        </group_list>
        <measure>
          <title>Event-Free Survival (EFS)</title>
          <description>Number of patients surviving without relapsed/progressive disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Relapsed/Progressive Disease</title>
        <description>Relapse/Progression defined as:
Nodes, liver, and/or spleen ≥50% increased or new by physical exam / imaging studies.
Circulating lymphocytes ≥50% increased by morphology and/or flow cytometry. Richter's transformation by lymph node biopsy .</description>
        <time_frame>1 year post-autograft</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Autologous HCT, Donor HCT)</title>
            <description>Allogeneic Bone Marrow Transplantation: Undergo donor HCT
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant
Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT
Carmustine: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative study
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Peripheral Blood Stem Cell Transplantation: Undergo donor HCT
Tacrolimus: Given IV or PO
Total-Body Irradiation: Undergo TBI</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Relapsed/Progressive Disease</title>
          <description>Relapse/Progression defined as:
Nodes, liver, and/or spleen ≥50% increased or new by physical exam / imaging studies.
Circulating lymphocytes ≥50% increased by morphology and/or flow cytometry. Richter's transformation by lymph node biopsy .</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Number of patients surviving one year post-autograft</description>
        <time_frame>1 year post-autograft</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Autologous HCT, Donor HCT)</title>
            <description>Allogeneic Bone Marrow Transplantation: Undergo donor HCT
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant
Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT
Carmustine: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative study
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Peripheral Blood Stem Cell Transplantation: Undergo donor HCT
Tacrolimus: Given IV or PO
Total-Body Irradiation: Undergo TBI</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Number of patients surviving one year post-autograft</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Grade II-IV Acute Graft-versus-Host-Disease and/or Chronic Extensive Graft-versus-Host-Disease</title>
        <description>aGVHD The diagnosis of aGVHD is identified through various stages and grading of the disease related to Skin (Rash), Gut (Diarrhea, Nausea/vomiting and/or anorexia) and the liver (Bilirubin) assessed by severity and grading scale outlined in the section Grafts vs Hosts by Sullivan (1999).
GVHD Grades Grade I: 1-2 Skin Rash; No gut or liver involvement Grade II: Stage 1-3 Skin rash; Stage 1 gut and/or stage 1 liver involvement Grade III: Stage 2-4 gut involvement and/or stage 2-4 liver involvement with or without rash Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death
CGVHD The diagnosis of cGVHD requires at least one manifestation that is distinctive for chronic GVHD as opposed to acute GVHD. In all cases, infection and others causes must be ruled out in the differential diagnosis of chronic GVHD.</description>
        <time_frame>1 year post-allograft,</time_frame>
        <population>Two patients are not evaluable for Graft-versus-Host-Disease due to disease progression; they failed the study and did not receive the allogeneic transplantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Autologous HCT, Donor HCT)</title>
            <description>Allogeneic Bone Marrow Transplantation: Undergo donor HCT
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant
Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT
Carmustine: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative study
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Peripheral Blood Stem Cell Transplantation: Undergo donor HCT
Tacrolimus: Given IV or PO
Total-Body Irradiation: Undergo TBI</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade II-IV Acute Graft-versus-Host-Disease and/or Chronic Extensive Graft-versus-Host-Disease</title>
          <description>aGVHD The diagnosis of aGVHD is identified through various stages and grading of the disease related to Skin (Rash), Gut (Diarrhea, Nausea/vomiting and/or anorexia) and the liver (Bilirubin) assessed by severity and grading scale outlined in the section Grafts vs Hosts by Sullivan (1999).
GVHD Grades Grade I: 1-2 Skin Rash; No gut or liver involvement Grade II: Stage 1-3 Skin rash; Stage 1 gut and/or stage 1 liver involvement Grade III: Stage 2-4 gut involvement and/or stage 2-4 liver involvement with or without rash Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death
CGVHD The diagnosis of cGVHD requires at least one manifestation that is distinctive for chronic GVHD as opposed to acute GVHD. In all cases, infection and others causes must be ruled out in the differential diagnosis of chronic GVHD.</description>
          <population>Two patients are not evaluable for Graft-versus-Host-Disease due to disease progression; they failed the study and did not receive the allogeneic transplantation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute Graft-versus-Host-Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic extensive Graft-versus-Host-Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality (NRM)</title>
        <description>Number of patients with non-relapse mortalities.</description>
        <time_frame>200 days and 1 Year post-allograft</time_frame>
        <population>Two patients are not evaluable for GVHD due to disease progression; they failed the study and did not receive the allogeneic transplantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Autologous HCT, Donor HCT)</title>
            <description>Allogeneic Bone Marrow Transplantation: Undergo donor HCT
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant
Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT
Carmustine: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative study
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Peripheral Blood Stem Cell Transplantation: Undergo donor HCT
Tacrolimus: Given IV or PO
Total-Body Irradiation: Undergo TBI</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality (NRM)</title>
          <description>Number of patients with non-relapse mortalities.</description>
          <population>Two patients are not evaluable for GVHD due to disease progression; they failed the study and did not receive the allogeneic transplantation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>200 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Engrafted</title>
        <description>Number of patients with donor engraftment.</description>
        <time_frame>Day 84 post-allograft</time_frame>
        <population>Two patients are not evaluable for GVHD due to disease progression; they failed the study and did not receive the allogeneic transplantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Autologous HCT, Donor HCT)</title>
            <description>Allogeneic Bone Marrow Transplantation: Undergo donor HCT
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant
Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT
Carmustine: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative study
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Peripheral Blood Stem Cell Transplantation: Undergo donor HCT
Tacrolimus: Given IV or PO
Total-Body Irradiation: Undergo TBI</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Engrafted</title>
          <description>Number of patients with donor engraftment.</description>
          <population>Two patients are not evaluable for GVHD due to disease progression; they failed the study and did not receive the allogeneic transplantation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Had Infections</title>
        <description>Number of patients who had infections.</description>
        <time_frame>1 Year post-autograft</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Autologous HCT, Donor HCT)</title>
            <description>Allogeneic Bone Marrow Transplantation: Undergo donor HCT
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant
Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT
Carmustine: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative study
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Peripheral Blood Stem Cell Transplantation: Undergo donor HCT
Tacrolimus: Given IV or PO
Total-Body Irradiation: Undergo TBI</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Had Infections</title>
          <description>Number of patients who had infections.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs: Conditioning through Day 100; SAEs: Conditioning through Day 200; All-Cause Mortality: Conditioning through 1 Year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Autologous HCT, Donor HCT)</title>
          <description>Allogeneic Bone Marrow Transplantation: Undergo donor HCT
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant
Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT
Carmustine: Given IV
Cyclophosphamide: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative study
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Peripheral Blood Stem Cell Transplantation: Undergo donor HCT
Tacrolimus: Given IV or PO
Total-Body Irradiation: Undergo TBI</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mohamed L. Sorror</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>(206) 667-6298</phone>
      <email>msorror@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

